Collegium Pharmaceutical (NASDAQ:COLL) Stock Rating Raised to “Strong-Buy” at Zacks Research

Posted by Brian Himes on Oct 17th, 2026

Zacks Research upgraded shares of Collegium Pharmaceutical (NASDAQ:COLL – Free Report) from a strong sell rating to a strong-buy rating in a research report released on Thursday,Zacks reports.

Several other research analysts have also recently weighed in on the stock. Wall Street Zen cut shares of Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Leerink Partners assumed coverage on Collegium Pharmaceutical in a research note on Wednesday, September 9th. They set an “outperform” rating and a $45.00 price objective for the company. Barclays reduced their target price on Collegium Pharmaceutical from $56.00 to $48.00 and set an “overweight” rating for the company in a research report on Wednesday, August 19th. Weiss Ratings lowered Collegium Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, September 4th. Finally, Piper Sandler restated a “neutral” rating and issued a $43.00 target price (down from $45.00) on shares of Collegium Pharmaceutical in a research note on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $48.71.

Check Out Our Latest Stock Report on COLL

Collegium Pharmaceutical Price Performance

COLL traded up $0.01 during trading on Thursday, reaching $23.19. 558,644 shares of the company were exchanged, compared to its average volume of 831,925. The company’s 50-day moving average is $24.07 and its two-hundred day moving average is $30.84. The company has a market cap of $755.07 million, a price-to-earnings ratio of 18.70, a P/E/G ratio of 0.72 and a beta of 0.73. The company has a quick ratio of 0.84, a current ratio of 1.03 and a debt-to-equity ratio of 3.32. Collegium Pharmaceutical has a 12-month low of $21.43 and a 12-month high of $50.79.

Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 earnings per share for the quarter, beating the consensus estimate of $1.72 by $0.20. The firm had revenue of $199.88 million for the quarter, compared to analysts’ expectations of $199.62 million. Collegium Pharmaceutical had a return on equity of 91.43% and a net margin of 5.93%. The company’s revenue was up 6.3% on a year-over-year basis. During the same period in the prior year, the business posted $1.68 earnings per share. Research analysts forecast that Collegium Pharmaceutical will post 6.42 earnings per share for the current fiscal year.

Institutional Trading of Collegium Pharmaceutical

Institutional investors and hedge funds have recently made changes to their positions in the stock. Caitong International Asset Management Co. Ltd increased its stake in Collegium Pharmaceutical by 205.3% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 635 shares of the specialty pharmaceutical company’s stock valued at $29,000 after acquiring an additional 427 shares during the last quarter. PNC Financial Services Group Inc. lifted its stake in Collegium Pharmaceutical by 42.2% during the first quarter. PNC Financial Services Group Inc. now owns 1,408 shares of the specialty pharmaceutical company’s stock worth $47,000 after purchasing an additional 418 shares during the last quarter. Assetmark Inc. lifted its stake in Collegium Pharmaceutical by 9.3% during the first quarter. Assetmark Inc. now owns 3,923 shares of the specialty pharmaceutical company’s stock worth $130,000 after purchasing an additional 335 shares during the last quarter. EverSource Wealth Advisors LLC boosted its holdings in shares of Collegium Pharmaceutical by 20.6% in the 1st quarter. EverSource Wealth Advisors LLC now owns 5,035 shares of the specialty pharmaceutical company’s stock worth $167,000 after purchasing an additional 861 shares in the last quarter. Finally, Allworth Financial LP purchased a new position in shares of Collegium Pharmaceutical in the 2nd quarter worth about $175,000.

About Collegium Pharmaceutical

(Get Free Report)

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on developing, acquiring and commercializing medicines for central nervous system disorders. The company’s portfolio is concentrated in pain management and includes products for chronic and acute pain, opioid-induced constipation and related conditions.

Collegium’s marketed products include Xtampza ER, an extended-release oxycodone formulation designed with the company’s DETERx abuse-deterrent technology; Nucynta and Nucynta ER, tapentadol products for acute and chronic pain; Belbuca, a buprenorphine buccal film for chronic pain; and Symproic, a treatment for opioid-induced constipation.